Current evidence on the use of anakinra in COVID-19.

Khani, Elnaz; Shahrabi, Marzieh; Rezaei, Haleh; Pourkarim, Fariba; Afsharirad, Hoda; Solduzian, Mohammad

Khani, Elnaz; Shahrabi, Marzieh; Rezaei, Haleh; Pourkarim, Fariba; Afsharirad, Hoda; Solduzian, Mohammad.

Afiliação

Khani E; Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Shahrabi M; Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Rezaei H; Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Pourkarim F; Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Afsharirad H; Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Solduzian M; Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: solduzianm@tbzmed.ac.ir.

Int Immunopharmacol ; 111: 109075, 2022 Oct.

Article em En | MEDLINE | ID: mdl-35905562

Assuntos

Tratamento Farmacológico da COVID-19; Síndrome da Liberação de Citocina/tratamento farmacológico; Citocinas; Humanos; Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico; Interleucina-1; SARS-CoV-2

Palavras-chave

Acute respiratory distress syndrome; Anakinra; COVID-19; Cytokine release syndrome; Interleukin-1; Multiple organ failure

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Int Immunopharmacol Assunto da revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google